Homemedication

medication

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

May 20, 2026

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

March 16, 2026